UNLABELLED: Autoradiography helps to determine the distribution and density of muscarinic receptor (MR) binding sites in the brain. However, it relies on the selectivity of radioligands toward their target. 3H-Pirenzepine is commonly believed to label predominantly M1MR, 3H-AFDX-384 is considered as M2MR selective ligand. Here we performed series of autoradiographies with 3H-AFDX-384 (2 nM), and 3H-pirenzepine (5 nM) in WT, M1KO, M2KO, and M4KO mice to address the ligand selectivity. Labeling with 3H-pirenzepine using M1KO, M2KO, and M4KO brain sections showed the high selectivity toward M1MR. Selectivity of 3H-AFDX-384 toward M2MR varies among brain regions and depends on individual MR subtype proportion. All binding sites in the medulla oblongata and pons, correspond to M2MR. In caudate putamen, nucleus accumbens and olfactory tubercle, 77.7, 74.2, and 74.6% of 3H-AFDX-384 binding sites, respectively, are represented by M4MR and M2MR constitute only a minor portion. In cortex and hippocampus, 3H-AFDX-384 labels almost similar amounts of M2MR and M4MR alongside significant amounts of non-M2/non-M4MR. In cortex, the proportion of 3H-AFDX-384 binding sites attributable to M2MR can be increased by blocking M4MR with MT3 toxin without affecting non-M4MR. PD102807, which is considered as a highly selective M4MR antagonist failed to improve the discrimination of M2MR. Autoradiography with 3H-QNB showed genotype specific loss of binding sites. IN CONCLUSION: while 3H-pirenzepine showed the high selectivity toward M1MR, 3H-AFDX-384 binding sites represent different populations of MR subtypes in a brain-region-specific manner. This finding has to be taken into account when interpreting the binding data.

1st Faculty of Medicine Institute of Physiology Charles University Prague Czechia

Institute of Experimental Botany Academy of Sciences of the Czech Republic Prague Czechia

Zobrazit více v PubMed

Aubert I., Cécyre D., Gauthier S., Quirion R. (1992). Characterization and autoradiographic distribution of [3H]AF-DX 384 binding to putative muscarinic M2 receptors in the rat brain. Eur. J. Pharmacol. 217, 173–184. 10.1016/0014-2999(92)90843-S PubMed DOI

Bodick N. C., Offen W. W., Shannon H. E., Satterwhite J., Lucas R., van Lier R., et al. . (1997). The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11(Suppl. 4), S16–S22. PubMed

Bradley S. J., Bourgognon J., Sanger H. E., Verity N., Mogg A. J., White D. J., et al. . (2017). M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. J. Clin. Invest. 127, 487–499. 10.1172/JCI87526 PubMed DOI PMC

Brady A. E., Jones C. K., Bridges T. M., Kennedy J. P., Thompson A. D., Heiman J. U., et al. . (2008). Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 327, 941–953. 10.1124/jpet.108.140350 PubMed DOI PMC

Buckley N. J., Bonner T. I., Brann M. R. (1988). Localization of a family of muscarinic receptor mRNAs in rat brain. J. Neurosci. 8, 4646–4652. PubMed PMC

Buckley N. J., Bonner T. I., Buckley C. M., Brann M. R. (1989). Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35, 469–476. PubMed

Buckley N. J., Burnstock G. (1986). Autoradiographic localization of peripheral M1 muscarinic receptors using [3H]pirenzepine. Brain Res. 375, 83–91. 10.1016/0006-8993(86)90961-3 PubMed DOI

Bymaster F. P., McKinzie D. L., Felder C. C., Wess J. (2003). Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 28, 437–442. 10.1023/A:1022844517200 PubMed DOI

Castoldi A. F., Fitzgerald B., Manzo L., Tonini M., Costa L. G. (1991). Muscarinic M2 receptors in rat brain labeled with [3H] AF-DX 384. Res. Commun. Chem. Pathol. Pharmacol. 74, 371–374. PubMed

Cea-del Rio C. A., Lawrence J. J., Tricoire L., Erdelyi F., Szabo G., McBain C. J. (2010). M3 Muscarinic acetylcholine receptor expression confers differential cholinergic modulation to neurochemically distinct hippocampal basket cell subtypes. J. Neurosci. 30, 6011–6024. 10.1523/JNEUROSCI.5040-09.2010 PubMed DOI PMC

Cortes R., Palacios J. M. (1986). Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies. Brain Res. 362, 227–238. 10.1016/0006-8993(86)90448-8 PubMed DOI

Dall C., Weikop P., Dencker D., Molander A. C., Conn P. J., Fink-Jensen A., et al. (2017). Wörtwein, G., and Muscarinic receptor M4 positive allosteric modulators attenuate central effects of cocaine. Drug Alcohol Depend 176, 154–161. 10.1016/j.drugalcdep.2017.03.014 PubMed DOI PMC

Dong G. Z., Kameyama K., Rinken A., Haga T. (1995). Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J. Pharmacol. Exp. Ther. 274, 378–384. PubMed

Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M. R. (1991). Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256, 727–733. PubMed

Eglen R. (2012). Overview of muscarinic receptor subtypes, in Muscarinic Receptors, eds Fryer A. D., Christopoulos A., Nathanson N. M. (Berlin; Heidelberg: Springer; ), 3–28.

Entzeroth M., Mayer N. (1990). Labeling of rat heart muscarinic receptors using the new M2 selective antagonist [3H]AF-DX 384. Biochem. Pharmacol. 40, 1674–1676. 10.1016/0006-2952(90)90473-X PubMed DOI

Farar V., Mohr F., Legrand M., d'Incamps B. L., Cendelin J., Leroy J., et al. . (2012). Near-complete adaptation of the PRiMA knockout to the lack of central acetylcholinesterase. J. Neurochem. 122, 1065–1080. 10.1111/j.1471-4159.2012.07856.x PubMed DOI

Farar V., Myslivecek J. (2016). Autoradiography assessment of muscarinic receptors in the central nervous system, in Muscarinic Receptor: From Structure to Animal Models, eds Myslivecek J., Jakubik J. (New York, NY: Springer; ), 159–180.

Ferrari-Dileo G., Waelbroeck M., Mash D. C., Flynn D. D. (1994). Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. Mol. Pharmacol. 46, 1028–1035. PubMed

Flynn D. D., Mash D. C. (1993). Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 14, 283–296. 10.1002/syn.890140406 PubMed DOI

Gomeza J., Shannon H., Kostenis E., Felder C., Zhang L., Brodkin J., et al. . (1999a). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 1692–1697. 10.1073/pnas.96.4.1692 PubMed DOI PMC

Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., et al. (1999b). Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 10483–10488. 10.1073/pnas.96.18.10483 PubMed DOI PMC

Grailhe R., Cardona A., Even N., Seif I., Changeux J.-P., Cloëz-Tayarani I. (2009). Regional changes in the cholinergic system in mice lacking monoamine oxidase A. Brain Res. Bull. 78, 283–289. 10.1016/j.brainresbull.2008.12.004 PubMed DOI

Hersch S. M., Gutekunst C. A., Rees H. D., Heilman C. J., Levey A. I. (1994). Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. neurosci. 14, 3351–3363. PubMed PMC

Jositsch G., Papadakis T., Haberberger R. V., Wolff M., Wess J., Kummer W. (2009). Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 379, 389–395. 10.1007/s00210-008-0365-9 PubMed DOI PMC

Kow R. L., Nathanson N. M. (2012). Structural biology: muscarinic receptors become crystal clear. Nature 482, 480–481. 10.1038/482480a PubMed DOI

Kruse A. C., Ring A. M., Manglik A., Hu J., Hu K., Eitel K., et al. . (2013). Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101–106. 10.1038/nature12735 PubMed DOI PMC

Langmead C. J., Watson J., Reavill C. (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117, 232–243. 10.1016/j.pharmthera.2007.09.009 PubMed DOI

Levey A. I. (1996). Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 93, 13541–13546. 10.1073/pnas.93.24.13541 PubMed DOI PMC

Levey A. I., Kitt C. A., Simonds W. F., Price D. L., Brann M. R. (1991). Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11, 3218–3226. PubMed PMC

Manuel I., Barreda-Gómez G., González De San Román E., Veloso A., Fernández J. A., Giralt M. T., et al. . (2015). Neurotransmitter receptor localization: from autoradiography to imaging mass spectrometry. ACS Chem. Neurosci. 6, 362–373. 10.1021/cn500281t PubMed DOI

McCabe R. T., Gibb J. W., Wamsley J. K., Hanson G. R. (1987). Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment. Brain Res. Bull. 19, 551–557. 10.1016/0361-9230(87)90072-4 PubMed DOI

Mulugeta E., Karlsson E., Islam A., Kalaria R., Mangat H., Winblad B., et al. . (2003). Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res. 960, 259–262. 10.1016/S0006-8993(02)03542-4 PubMed DOI

Myslivecek J., Klein M., Novakova M., Ricny J. (2008). The detection of the non-M-2 muscarinic receptor subtype in the rat heart atria and ventricles. Naunyn-Schmiedebergs Arch. Pharmacol. 378, 103–116. 10.1007/s00210-008-0285-8 PubMed DOI

Nieves-Martinez E., Haynes K., Childers S. R., Sonntag W. E., Nicolle M. M. (2012). Muscarinic receptor/G-protein coupling is reduced in the dorsomedial striatum of cognitively impaired aged rats. Behav. Brain Res. 227, 258–264. 10.1016/j.bbr.2011.10.048 PubMed DOI PMC

Oki T., Takagi Y., Inagaki S., Taketo M. M., Manabe T., Matsui M., et al. (2005). Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Mol. Brain Res. 133, 6–11. 10.1016/j.molbrainres.2004.09.012 PubMed DOI

Peralta E. G., Ashkenazi A., Winslow J. W., Smith D. H., Ramachandran J., Capon D. J. (1987). Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 6, 3923–3929. PubMed PMC

Pradidarcheep W., Michel M. C. (2016). Use of antibodies in the research on muscarinic receptor subtypes, in Muscarinic Receptor: From Structure to Animal Models, eds Myslivecek J., Jakubik J. (New York, NY: Springer; ), 83–94.

Reiner C., Nathanson N. (2012). Muscarinic receptor trafficking, in Muscarinic Receptors, eds Fryer A. D., Christopoulos A., Nathanson N. M. (Berlin; Heidelberg: Springer; ), 61–78. PubMed

Scarr E., Dean B., Der Zee E. A., Luiten P. G. (1999). Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J. Neurochem. 107, 1188–1195. 10.1111/j.1471-4159.2008.05711.x PubMed DOI

Shin J. H., Adrover M. F., Wess J., Alvarez V. A. (2015). Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 112, 8124–8129. 10.1073/pnas.1508846112 PubMed DOI PMC

Thomsen M., Sørensen G., Dencker D. (2017). Physiological roles of CNS muscarinic receptors gained from knockout mice. Neuropharmacology. [Epub ahead of print]. 10.1016/j.neuropharm.2017.09.011 PubMed DOI PMC

Tice M. A., Hashemi T., Taylor L. A., McQuade R. D. (1996). Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Dev. Brain Res. 92, 70–76. 10.1016/0165-3806(95)01515-9 PubMed DOI

Tien L.-T., Fan L.-W., Sogawa C., Ma T., Loh H. H., Ho I.-K. (2004). Changes in acetylcholinesterase activity and muscarinic receptor bindings in μ-opioid receptor knockout mice. Mol. Brain Res. 126, 38–44. 10.1016/j.molbrainres.2004.03.011 PubMed DOI PMC

Vilaró M. T., Palacios J. M., Mengod G. (1990). Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett. 114, 154–159. 10.1016/0304-3940(90)90064-G PubMed DOI

Villiger J. W., Faull R. L. M. (1985). Muscarinic cholinergic receptors in the human spinal cord: differential localization of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding sites. Brain Res. 345, 196–199. 10.1016/0006-8993(85)90854-6 PubMed DOI

Wamsley J. K., Gehlert D. R., Roeske W. R., Yamamura H. I. (1984). Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine. Life Sci. 34, 1395–1402. 10.1016/0024-3205(84)90012-2 PubMed DOI

Wang Q., Wei X., Gao H., Li J., Liao J., Liu X., et al. . (2014). Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory. Neuroscience 267, 57–66. 10.1016/j.neuroscience.2014.02.031 PubMed DOI

Watson M., Roeske W. R., Johnson P. C., Yamamura H. I. (1984). [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia. Brain Res. 290, 179–182. 10.1016/0006-8993(84)90751-0 PubMed DOI

Weiner D. M., Levey A. I., Brann M. R. (1990). Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl. Acad. Sci. U.S.A. 87, 7050–7054. 10.1073/pnas.87.18.7050 PubMed DOI PMC

Wess J., Duttaroy A., Zhang W., Gomeza J., Cui Y., Miyakawa T., et al. . (2003). M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Recept. Channels 9, 279–290. 10.3109/10606820308262 PubMed DOI

Wess J., Eglen R. M., Gautam D. (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6, 721–733. 10.1038/nrd2379 PubMed DOI

Wolff S. C., Hruska Z., Nguyen L., Dohanich G. P. (2008). Asymmetrical distributions of muscarinic receptor binding in the hippocampus of female rats. Eur. J. Pharmacol. 588, 248–250. 10.1016/j.ejphar.2008.04.002 PubMed DOI

Yamamura H. I., Wamsley J. K., Deshmukh P., Roeske W. R. (1983). Differential light microscopic autoradiographic localization of muscarinic cholinergic receptors in the brainstem and spinal cord of the rat using [3H]pirenzepine. Eur. J. Pharmacol. 91, 147–149. 10.1016/0014-2999(83)90379-5 PubMed DOI

Yasuda R. P., Ciesla W., Flores L. R., Wall S. J., Li M., Satkus S. A., et al. . (1993). Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol. Pharmacol. 43, 149–157. PubMed

Zavitsanou K., Katsifis A., Mattner F., Huang X.-F. (2003). Investigation of M1//M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29, 619–625. 10.1038/sj.npp.1300367 PubMed DOI

Zhang W., Basile A. S., Gomeza J., Volpicelli L. A., Levey A. I., Wess J. (2002). Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci. 22, 1709–1717. PubMed PMC

Multitargeting nature of muscarinic orthosteric agonists and antagonists

Social Isolation: How Can the Effects on the Cholinergic System Be Isolated?

Lack of M4 muscarinic receptors in the striatum, thalamus and intergeniculate leaflet alters the biological rhythm of locomotor activity in mice

Variability in the Drug Response of M4 Muscarinic Receptor Knockout Mice During Day and Night Time

The deletion of M4 muscarinic receptors increases motor activity in females in the dark phase